

The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth

<https://marketpublishers.com/r/U8CF6A26BE3EN.html>

Date: June 2014

Pages: 144

Price: US\$ 900.00 (Single User License)

ID: U8CF6A26BE3EN

Abstracts

The report titled “The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth” provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market.

The US Anti Cancer Drug market is the largest market in the world which has registered a positive growth rate over the period. The rising growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing number of cancer cases although many major drugs which lost their patent protection has hampered the growth of the market. The US Anti Cancer Drug Market has recorded a 5 year CAGR of 6.50% over the period. The sales of anti cancer drugs in the US grew from USD ~ billion in 2008 to USD ~ billion in 2013.

The Breast Cancer Drug Market is one of largest markets in terms of breast cancer drug sales with a global share of 59% and was valued at USD ~ billion in 2013. The breast cancer drug market though had a busy pipeline but has been mainly driven by sales of three major drugs namely Arimidex, Herceptin and Afinitor in recent years. Pancreatic cancer is one of the most researched segments as it cannot be diagnosed in a time leading to a fall in its survival rates. Avastin, Rituxan, Herceptin and Alimta were among

the world's top selling anti cancer drugs and each recorded sales above USD ~ million in the US in 2013.

The anti-cancer drug market of US is highly fragmented. The major players are continuously adopting diverse strategies in order to maintain their competitive edge especially when it comes to competition from generic drugs. Roche is the largest company in the US in terms of anti cancer drugs sales. The company held a market share of ~% and recorded sales of USD ~ million.

The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with projected sales of USD ~ billion in 2018. It is estimated that the research and development productivity will increase and will trigger the growth in the market. The companies will focus on developing pharmaceutical drugs for personalized healthcare.

KEY TOPICS COVERED IN THE REPORT

The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved.

The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market

Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs

Government Regulations in the US Anti Cancer Drug Market.

Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US

Revenues of Major Players in US Anti Cancer Drugs Market.

Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US.

Contents

1. ANTI-CANCER DRUGS MARKET INTRODUCTION

- 1.1. Global Scenario
- 1.2. Domestic Scenario
 - 1.2.1. Overview
 - 1.2.2. Research & Development Pipeline
 - Acquisition of Potential Compounds
 - Drug Screening and Pre Clinical Pharmacology
 - Clinical Trials

2. PREVALENCE OF DIFFERENT TYPES OF CANCERS IN THE US

- 2.1. By Number of New Cancer Cases, 2008 -2013
- 2.2. By Major Types of Cancer, 2008-2013
 - Cases of Breast Cancer
 - Cases of Pancreatic Cancer
 - Cases of Colon Cancer
 - Cases of Lung Cancer
 - Cases of Blood Cancer
 - Cases of Brain Cancer

3. THE US ANTI-CANCER DRUG MARKET SIZE

- 3.1. By Industry Sales, 2008-2013
- 3.2. By Number of Drugs Approved, 2008-2013
- 3.3. By Number of Cancer Drugs in Development, 2009 -2013

4. THE US ANTI-CANCER DRUG MARKET SEGMENTATION

- 4.1. By Types of Cancers (Blood, Breast, Colon, Lung, brain and Pancreatic Cancer), 2010-2013
- 4.2. By Oral Drugs and Injectables, 2013
- 4.3. By Cost of Therapies, 2013
 - Chemotherapy
 - Stem Cell Transplant
 - Targeted therapy
 - Immunotherapy

Hormone Therapy

4.4. By Generic and Patented Drugs, 2013

5. THE US BLOOD CANCER DRUG MARKET INTRODUCTION

5.1. The US Blood Cancer Drug Market Size, 2008-2013

Sales of Major Brain-Cancer Treatment Drugs (Rituxan, Revlimid, Velcade, Sprycel, Vidaza), 2008-2013

5.2. By Treatment and Side Effects

Treatment Cycle

Side Effects

5.3. By Patents and Expiry

6. THE US BREAST CANCER DRUGS MARKET INTRODUCTION

6.1. The US Breast Cancer Drugs Market Size, 2008-2013

By Sales of Major Cancer Drugs, 2008-2013

6.2. Treatment Process and Side Effects

Treatment Process

Side Effects

6.3. Patents and Expiry

7. THE US COLON CANCER DRUGS MARKET INTRODUCTION

7.1. The US Colon Cancer Drug Market Size, 2009-2013

Sales of Major Anti-Colon Cancer Drugs in The US, 2009-2013

7.2. Treatment and Side Effects

Treatment Cycle

Side Effects

7.3. Patents and Expiry

8. THE US BRAIN CANCER DRUGS MARKET INTRODUCTION

8.1. The US Brain Cancer Drugs Market Size, 2009-2013

Sales of Major Brain-Cancer Drugs in the US, 2009-2013

8.2. By Treatment and Side Effects

Treatment Cycle

Side Effects

8.3. By Patents and Expiry

9. THE US LUNG CANCER DRUGS MARKET INTRODUCTION

9.1. The US Lung Cancer Drugs Market Size, 2008-2013

9.1.1. Sales of Major Cancer Drugs, 2008-2013

9.2. By Small Cell Lung Cancer and Non Small Cell Lung Cancer, 2013

9.3. Treatment Process and Side Effects

The Treatment Cycle of Lung Cancer

Side Effects

9.4. Patents and Expiry

10. THE US PANCREATIC CANCER DRUGS MARKET INTRODUCTION

10.1. The US Pancreatic Cancer Drugs Market Size, 2008-2013

Sales of Major Pancreatic Cancer Drugs in the US, 2008-2013

10.2. Treatment Process and Side Effects

Treatment Cycle of Pancreatic Cancer

Side Effects

10.3. Patents and Expiry

11. TRENDS AND DEVELOPMENTS

12. REGULATIONS IN THE US ANTI-CANCER DRUG MARKET

Federal and State Regulations

13. SWOT ANALYSIS

14. GROWTH DRIVERS AND RESTRAINTS

14.1. Growth Drivers

14.2. Restraints

15. THE US ANTI-CANCER DRUGS INDUSTRY COMPETITIVE LANDSCAPE

15.1. Market Share of Major Players by Revenue, 2010- 2013

15.2. Sales of Major Brands, Patents and Comparative Analysis of Major Pharmaceutical Companies, 2013

16. COMPANY PROFILES

16.1. Pfizer

16.1.1. Business Overview

16.1.2. Business Strategies

16.1.3. Financial Performance, 2009-2013

Anti-cancer Drug profile

Cancer Drug Pipeline

16.2. Novartis

16.2.1. Business Overview

16.2.2. Business Strategies

16.2.3. Financial Performance, 2009-2013

Anti-Cancer Drug Profile

Cancer Drug pipeline

16.3. Roche

16.3.1. Business Overview

16.3.2. Business Strategies

16.3.3. Financial Performance, 2010-2013

Anti-Cancer Drug Profile

Cancer Drug Pipeline

16.4. Astra Zeneca

16.4.1. Business Overview

16.4.2. Business Strategies

16.4.3. Financial Performance, 2009-2013

Anti-Cancer Drug Profile

Cancer Drug Pipeline

16.5. Bristol-Myers Squibb

16.5.1. Business Overview

16.5.2. Business Strategies

16.5.3. Financial Performance, 2009-2013

Anti-Cancer Drug Profile

Cancer Drug Pipeline

16.6. Amgen

16.6.1. Business Overview

16.6.2. Business Strategies

16.6.3. Financial Performance, 2009-2013

Anti-Cancer Drug Profile

Cancer Drug Pipeline

16.7. Merck & Company

- 16.7.1. Business Overview
- 16.7.2. Business Strategies
- 16.7.3. Financial Performance, 2009-2013
 - Anti-Cancer Drug Profile
 - Cancer Drug pipeline
- 16.8. Celgene
 - 16.8.1. Business Overview
 - 16.8.2. Business Strategies
 - 16.8.3. Financial Performance, 2009-2013
 - Anti-Cancer Drug Profile
 - Cancer Drug Pipeline
- 16.9. Sanofi-Aventis
 - 16.9.1. Business Overview
 - 16.9.2. Business Strategies
 - 16.9.3. Financial Performance, 2009-2013
 - Anti-Cancer Drug Profile
 - Cancer Drug Pipeline
- 16.10. Eli Lilly
 - 16.10.1. Business Overview
 - 16.10.2. Business Strategies
 - 16.10.3. Financial Performance, 2009-2013
 - Anti-Cancer Drug Profile
 - Cancer Drug Pipeline
- 16.11. GlaxoSmithKline
 - 16.11.1. Business Overview
 - 16.11.2. Business Strategies
 - 16.11.3. Financial Performance, 2009-2013
 - Anti-Cancer Drug Profile
 - Cancer Drug Pipeline

17. THE US ANTI-CANCER DRUG MARKET FUTURE OUTLOOK

Overall Market Predictions, 2014 - 2018

Role of the Government in the Future

Competition Expected to Evolve in Future

17.1. Cause and Effect Relationship between Independent and Dependent Factors

17.2. The US Anti-Cancer Drug Market Future Projections by Cancer Types, 2014-2018

17.3. Future Projections by Generic and Patented Drugs, 2018

18. MACRO-ECONOMIC FACTORS AFFECTING THE US ANTI-CANCER DRUGS MARKET

- 18.1. National Healthcare Spending, 2008-2018
- 18.2. Upper Class Population of the US, 2008-2018
- 18.3. Number of Oncologists in the US, 2008-2018
- 18.4. Consumer Expenditure on Healthcare, 2008-2018

19. APPENDIX

- 19.1. Market Definition
- 19.2. Abbreviations
- 19.3. Research Methodology
 - Data Collection Methods
 - Approach
 - Variables (Dependent and Independent)
 - Final Conclusion
- 19.4. Disclaimer

List Of Figures

LIST OF FIGURES

Figure 1: Global Sales of Anti-Cancer Drugs in USD Billion, 2009-2013

Figure 2: Anti-cancer Drug Development and Approval Process in the US

Figure 3: US Anti-Cancer Drugs Market Size on the Basis of Industry Revenue in USD Million, 2008-2013

Figure 4: Number of Anti-Cancer Drugs in Development in the US, 2009-2013

Figure 5: Revenue of Pfizer from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 6: Revenues of Novartis from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 7: Revenues of Roche from Sales Anti-Cancer Drugs in the US in USD Million, 2010-2013

Figure 8: Revenues of Astra Zeneca from Sales Anti-Cancer Drugs in the US in USD Million, 2009-2013

Figure 9: Revenues of Bristol-Myers Squibb from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 10: Revenues of Amgen from Sales Anticancer Drugs in the US in USD Million, 2009-2013

Figure 11: Revenues of Merck and Company from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 12: Revenues of Celgene from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 13: Revenues of Sanofi-Aventis from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 14: Revenues of Eli-Lilly from Sales of Anti-cancer Drug in the US in USD Million, 2009-2013

Figure 15: Revenues from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013

Figure 16: The US Anti-cancer Drug Industry Future Projections on the Basis of Sales in USD Million, 2014-2018

Figure 17: The US Anti-cancer Drug Industry Future Projections by Generic and Patented Drugs on the Basis of Revenue Contribution in Percentage, 2018

Figure 18: US National Healthcare Spending in USD Billion, 2008-2018

Figure 19: Upper Class Population of US in Thousand, 2008-2018

Figure 20: Number of Oncologists in US in Thousand, 2008-2018

Figure 21: Consumer Expenditure on Healthcare in the US in USD Million, 2008-2018

List Of Tables

LIST OF TABLES

Table 1: Average Cost of Treatment of Cancer in USD
Table 2: Anti-cancer Drugs in Pipeline
Table 3: Number of New Cancer Cases in US, 2008-2013
Table 4: Number of New Cases of Cancer in the US by Types of Cancers, 2008-2013
Table 5: Number of Anti Cancer Drugs Approved in the US, 2008-2013
Table 6: The US Anti Cancer Drug Market Segmentation by Types of Cancer by Industry Revenue in USD Million, 2010-2013
Table 7: Prices of Injectable Drugs in US by Cycle in USD, 2013
Table 8: Prices of Oral Drugs in US by Cycle in USD
Table 9: Cost of Cancer Therapies in USD, 2013
Table 10: Drugs Used for the Different Types of Cancer Therapies
Table 11: The US Anti Cancer Drug Market Segmentation by Generic and Patented Drugs on the Basis of Sales in USD Million and Contribution in Percentage, 2013
Table 12: Cost of Generic Drugs in USD, 2012
Table 13: Sales of Major Blood Cancer Drugs in USD Million, 2008-2013
Table 14: Prices of Major Blood Cancer Drugs per Cycle in USD, 2013
Table 15: Leukemia Survival by Stage in Percentage
Table 16: Approval and Expiry of Blood Cancer Drugs
Table 17: Sales of Major Breast Cancer Drugs in the US in USD Million, 2008-2013
Table 18: Prices of Major Breast Cancer Drugs per Cycle in USD, 2013
Table 19: Breast Cancer Survival by Stage in Percentage
Table 20: Approval and Expiry Periods of Major Breast Cancer Drugs in the US
Table 21: Sales of Major Colon Cancer Drugs in the US in USD Million, 2009-2013
Table 22: Prices of Major Colon Cancer Drugs per Cycle in USD, 2013
Table 23: Colon Cancer Survival Rate by Stage in Percentage
Table 24: Approvals and Expiry for Colon Cancer Drugs
Table 25: Sales of Major Brain Cancer Drugs in USD Million, 2009-2013
Table 26: Prices of Major Brain Cancer Drugs per Cycle in USD, 2013
Table 27: Brain Cancer Survival by Age in Percentage
Table 28: Approval and Expiry for Brain Cancer Drugs
Table 29: Sales of Major Lung Cancer Drugs in the US in USD Million, 2008-2013
Table 30: Prices of Major Lung Cancer Drugs per Cycle in USD, 2013
Table 31: The US Anti- Lung Cancer Drugs Market Segmentation by Small Cell Lung Cancer and Non Small Cell Lung Cancer on the Basis of Revenue Contribution in USD Million & Percentage, and Incidence Rates in the US, 2013

Table 32: Lung Cancer Survival by Stage

Table 33: Approval and Expiry Period of Major Lung Cancer Drugs in the US

Table 34: Sales of Major Pancreatic Cancer Drugs in USD Million, 2008-2013

Table 35: Prices of Major Pancreatic Cancer Drugs per Cycle in USD, 2013

Table 36: Exocrine Pancreatic Cancer Survival by Stage in Percentage

Table 37: Neuro-Endocrine Pancreatic Cancer Treated with Surgery Survival by Stage in Percentage

Table 38: Approval and Expiry Period of Major Pancreatic Cancer Drugs in the US

Table 39: US Anti-cancer Drug Market SWOT Analysis

Table 40: Market Shares of Major players by Revenue Contribution in the US Anti-Cancer Drugs Market in Percentage, 2010-2013

Table 41: Revenues of Major players in the US Anti-Cancer Drugs Market in USD Million, 2010-2013

Table 42: Comparative Analysis of Major Players on the basis of Major Drugs, Number of Patents and Sales of Major Drugs in USD Million, 2013

Table 43: Global Research and Development Expenses of Pfizer in USD Million, 2009-2013

Table 44: Anti-cancer Drug Portfolio of Pfizer

Table 45: Pfizer Anti-cancer Drug Pipeline

Table 46: Global Research and Development Expenses of Novartis in USD Million, 2009-2013

Table 47: Anti-cancer Drug Profile of Novartis

Table 48: Novartis Cancer Drug Pipeline

Table 49: Global Research and Development Expenses of Roche in USD Million, 2009-2013

Table 50: Roche Anti-cancer Drug Portfolio

Table 51: Cancer Drug Pipeline of Roche

Table 52: Anti-cancer Drug Portfolio

Table 53: Anti-cancer Drug Pipeline

Table 54: Global Research and Development Expenses of Bristol Myers-Squibb in USD Million, 2009-2013

Table 55: Anti-cancer Drug Portfolio

Table 56: Cancer Drug Pipeline

Table 57: Global Research and Development Expenses of Amgen in USD Million, 2009-2013

Table 58: Anti-cancer Drug Portfolio of Amgen

Table 59: Cancer Drug Pipeline of Amgen

Table 60: Global Research and Development Expenses of Merck and Co. in USD Million, 2009-2013

Table 61: Anti-cancer Drug Portfolio of Merck & Co

Table 62: Cancer Drug Pipeline of Merck & Co.

Table 63: Global Research and Development Expenses of Celgene in USD Million, 2009-2013

Table 64: Anti-cancer Drug Portfolio of Celgene

Table 65: Cancer Drug Pipeline of Celgene

Table 66: Global Research and Development Expenses of Sanofi-Aventis in USD Million, 2009-2013

Table 67: Anti-cancer Drug Portfolio of Sanofi

Table 68: Cancer Drug Pipeline

Table 69: Global Research and Development Expenses of Eli-Lilly in USD Million, 2009-2013

Table 70: Anti-cancer Drug Portfolio

Table 71: Cancer Drug Pipeline

Table 72: Global Research Development Expenses of GalaxoSmith Kline in USD Million, 2011-2013

Table 73: GlaxoSmithKline Anti-cancer Drug Profile

Table 74: Cancer Drug Pipeline of GlaxoSmithKline

Table 75: Anti Cancer Drug Patent Expirations, 2013-2018

Table 76: Anti Cancer Drugs to Be Launched During 2013-2018

Table 77: Cause and Effect Relationship between Industry Factors and the US Anti-cancer Drug Market Prospects

Table 79: The US Anti Cancer Drug Industry Future Projections by Type of Cancer (Blood, Breast, Colon, Pancreatic, Lung and Brain Cancer) in USD Million, 2014-2018

Table 78: The US Anti Cancer Drug Industry Future Projections on the Basis of Number of Cancer Cases, 2014-2018

Table 80: Correlation Matrix of US Anti-Cancer Drug Market

Table 81: Regression Coefficients Output

I would like to order

Product name: The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth

Product link: <https://marketpublishers.com/r/U8CF6A26BE3EN.html>

Price: US\$ 900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U8CF6A26BE3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

